BioCentury
ARTICLE | Company News

Renaissance Acquisition Holdings LLC, GlaxoSmithKline sales and marketing update

June 17, 2013 7:00 AM UTC

GlaxoSmithKline granted Renaissance rights to market six approved dermatology drugs and three formulations of Zovirax acyclovir in the U.S. The dermatology products are Evoclin clindamycin, a foam formulation of 1% clindamycin to treat infections; Extina 2% ketoconazole topical foam to treat seborrheic dermatitis in immunocompetent patients; topical steroid Olux clobetasol to treat psoriasis; Luxiq betamethasone to treat scalp dermatoses; Olux-E clobetasol propionate foam 0.05% to treat psoriasis, scalp dermatoses and corticosteroid-responsive dermatoses; and Vusion miconazole, a topical cream made of 0.25% antifungal miconazole nitrate in a zinc oxide petrolatum base to treat infants and children with diaper dermatitis complicated by candidiasis. Renaissance also received rights to the capsule, tablet and suspension formulations of Zovirax, a synthetic nucleoside analog for cold sores. Renaissance's Prestium Pharma branded division will market the products in the U.S. Renaissance, a portfolio company of RoundTable Healthcare Partners (Lake Forest, Ill.), focuses on contract development and manufacturing and commercializing branded and generic prescription products in the U.S. and Canada. GSK declined to disclose details, and Renaissance could not be reached. ...